NVG308

Novelgen Technology

ALL-IN-ONE APPROACH

An innovative paradigm shift in viral treatment and prevention is needed! What if there were an effective therapeutic against all viruses?

Novelgen Co., Ltd. has developed NVG308, a broad-spectrum antiviral therapeutic capable of preventing and treating diseases caused by various viral infections, regardless of viral genotype. NVG308 is a nucleic acid hydrolyzing mini-antibody that shows therapeutic activity against diverse viruses, regardless of genetic mutations or resistance to existing therapeutics.

Novelgen is particularly focused on developing antiviral therapeutics capable of preventing and treating Influenza and Avian Influenza, which are causing problems for both humans and animals worldwide, while also conducting research to develop treatments for newly emerging novel viruses.

To realize this new concept of viral prevention and treatment development, Novelgen has established an international joint research collaboration network with renowned universities and research institutions both domestically and abroad, striving to create a world free from viral diseases.

3 Key Properties of 3D8 scFv

①

Viral Nucleic Acid Hydrolysis

Directly hydrolyzes viral nucleic acids (DNA, RNA). Acts broadly regardless of genotype, enabling immediate response to variant and resistant viruses.

②

Cell Membrane Penetration

Naturally penetrates into cells by binding to cell surface proteins without a separate drug delivery system (DDS). Independently overcomes a key barrier in therapeutic development.

③

Intestinal and Pulmonary Epithelial Cell Penetration

Effectively penetrates intestinal and pulmonary epithelial cells, enabling drug development via various administration routes: oral, inhalation, and injection.

Technological Potential

Effective response to locally and regionally emerging viruses worldwide is possible.

▸

Early response to viruses without developed vaccines or treatments(New viruses, mutant viruses, newly introduced viruses, etc.)

▸Application as a therapeutic for rare viruses occurring locally or regionally

Novelgen's innovative antibody shows broad antiviral activity regardless of the type of infecting viral genome, with the potential to become a blockbuster surpassing Tamiflu sales (USD 15.5 billion) as a leading neuraminidase inhibitor (NA-inhibitor).

Various prescriptions and applications are possible, including therapeutics, vaccine adjuvants, and alternatives.

1. Monotherapy2. Combination with NA-inhibitor3. Treatment of resistant viruses4. Severe influenza post-vaccination5. Influenza prophylaxis

Novelgen's developed antiviral therapeutics are expected to overcome the fundamental limitations of existing influenza prevention and treatment (such as resistant viruses), while providing response capability against highly pathogenic viruses that unexpectedly emerge in humans.

💡

Using Novelgen's innovative antibody platform, new drug development for various viral diseases is possible, including Zika virus, MERS, tick-borne viruses, Severe Fever with Thrombocytopenia Syndrome (SFTS), Hantavirus, and more.

View Roadmap →